Drugs / OpSCF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06101823 Comparator | Oct 2023 → Oct 2024 | atopic eczema | Opsidio, LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OpSCF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101823 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody, OpSCF” NCT06101823 ↗ |
| Route | Subcutaneous | “OpSCF, 600 mg, subcutaneously, every two weeks x 14 weeks” NCT06101823 ↗ |